West Pharmaceutical Services (NYSE:WST) Releases FY 2024 Earnings Guidance

West Pharmaceutical Services (NYSE:WST) updated its FY 2024 earnings guidance on Thursday. The company provided earnings per share guidance of 6.350-6.650 for the period, compared to the consensus earnings per share estimate of 7.740. The company issued revenue guidance of $2.9 billion-$2.9 billion, compared to the consensus revenue estimate of $3.0 billion.

West Pharmaceutical Services Trading Up 2.7 %

Shares of WST stock opened at $284.76 on Friday. The company has a current ratio of 2.61, a quick ratio of 1.95 and a debt-to-equity ratio of 0.03. West Pharmaceutical Services has a twelve month low of $265.00 and a twelve month high of $415.73. The company’s 50-day moving average price is $324.09 and its 200-day moving average price is $355.79. The stock has a market cap of $20.74 billion, a price-to-earnings ratio of 37.57, a PEG ratio of 6.03 and a beta of 1.00.

West Pharmaceutical Services (NYSE:WST) last posted its earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share for the quarter, missing the consensus estimate of $1.74 by ($0.22). The firm had revenue of $702.10 million during the quarter, compared to analyst estimates of $729.36 million. West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 18.78%. The business’s revenue for the quarter was down 6.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.11 earnings per share. As a group, equities analysts predict that West Pharmaceutical Services will post 6.4 earnings per share for the current year.

Insider Buying and Selling

In other West Pharmaceutical Services news, CEO Eric Mark Green sold 66,000 shares of West Pharmaceutical Services stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $366.65, for a total value of $24,198,900.00. Following the sale, the chief executive officer now owns 152,908 shares in the company, valued at $56,063,718.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Eric Mark Green sold 66,000 shares of the firm’s stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $366.65, for a total transaction of $24,198,900.00. Following the completion of the sale, the chief executive officer now directly owns 152,908 shares of the company’s stock, valued at approximately $56,063,718.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Silji Abraham sold 1,800 shares of the company’s stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $330.78, for a total transaction of $595,404.00. Following the completion of the transaction, the senior vice president now directly owns 2,860 shares in the company, valued at approximately $946,030.80. The disclosure for this sale can be found here. 0.53% of the stock is currently owned by company insiders.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.